Clinical Trial Update: Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122 [Phase 1]

View source ↗

Summary

Phase 1 study of the Shigella-ETEC vaccine strain CVD 1208S-122 (CVD 31000) completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enterotoxigenic Escherichia Coli Infection
• Shigellosis

Drugs mentioned

• CVD 1208S-122 Shigella-ETEC vaccine (Shigella-ETEC vaccine strain CVD 1208S-122)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Shigella Infection, Enterotoxigenic Escherichia Coli Infection | Phase 1 | Status: COMPLETED | Results posted: 2026-02-02